Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

Iovance Biotherapeutics Appoints Igor

Bilinsky as Chief Operating Officer

SAN CARLOS, Calif., Mar. 15, 2021 -- Iovance

Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies,

today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more

than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.

"I am pleased to welcome Igor to Iovance and look forward

to his contributions while we advance our TIL cell therapy pipeline," stated Maria Fardis, Ph.D., President and Chief Executive

Officer of Iovance Biotherapeutics. "Through his experience in several senior leadership roles across multiple functional

areas, Igor has led multiple teams across different companies, including internal manufacturing, and created significant shareholder

value. These capabilities are important to Iovance in furthering our leadership in TIL cell therapy development, manufacturing

and potential commercialization."

Dr. Bilinsky has more than 20 years of cumulative leadership

experience through prior roles as Chief Executive Officer, Chief Operating Officer, and Chief Business Officer at companies within

the life sciences industry. Most recently he served as Chief Business Officer of Oncternal Therapeutics, where he was integral

in building the publicly traded oncology company. Previously, Dr. Bilinsky served as Chief Operating Officer of AmpliPhi Biosciences,

and as General Manager and Senior Vice President at IGNYTA (now part of Roche). His prior experience also includes senior executive

roles at Vical and Halozyme Therapeutics, and Chief Executive Officer at Androclus Therapeutics. He also served as a principal

in the healthcare practice of Boston Consulting Group. Dr. Bilinsky received his B.S. in physics from the Moscow Institute of Physics

and Technology and his Ph.D. in physics from the Massachusetts Institute of Technology.

"I am very happy to join Iovance to help build the pipeline

for patients with cancer and spearhead the transition to internal manufacturing and potential commercialization," said Dr.

Bilinsky. "I believe TIL cell therapy has the potential to address broad cancer populations in multiple indications and at

various stages of disease. I look forward to applying my skillset across corporate operations to help continue development of TIL

therapy toward commercialization."

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment

of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune

cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process,

and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed

dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy

is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic

non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently

approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information,

please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking

statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us,"

or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All

such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements

and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing,

we may, in some cases, use terms such as "predicts," "believes," "potential," "continue,"

"estimates," "anticipates," "expects," "plans," "intends," "forecast,"

"guidance," "outlook," "may," "could," "might," "will,"

"should" or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking

statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience

and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.

Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update

or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are

not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our

control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different

from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments

and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors"

in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly

Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties

inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully

develop, submit, obtain and maintain U.S. Food and Drug Administration ("FDA") or other regulatory authority approval

of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates

for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from

ongoing clinical trials may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials;

the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory

agency input; the new version of the protocol which further defines the patient population to include more advanced patients in

our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct

additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities;

the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation

of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement

by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility

may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing

processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances

and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments,

not within our control.

Iovance Biotherapeutics, Inc:

Sara Pellegrino, IRC

Vice President, Investor Relations & Public Relations

650-260-7120 ext. 264

Chad Rubin (investors)

Zara Lockshin (media)